The plateau itself lasted through week 48 with an average regain of only 0.8 kilograms, demonstrating ongoing maintenance effects
This suggested a protective potential of the peptide against such injuries
Currently, semaglutide and tirzepatide are two of the most widely utilized GLP-1 RAs for type 2 diabetes and both are supported by robust data from phase 3 clinical trials 47
A Phase 2a trial (NCT06850727) organized as a two-part, open-label and randomized study evaluating the safety and efficacy of OD-07656 followed by vedolizumab therapy in patients with moderately to severely active UC, with primary outcomes measuring changes in the 3-component mMS from baseline to 12 weeks and treatment-emergent AEs
Han KA, Chon S, Chung CH, Lim S, Lee KW, Baik S, et al